EVFM — Evofem Biosciences Share News
0.000.00%
Last trade - 00:00- $0.83m
- $59.92m
- $20.18m
Brief: Nasdaq Accepts Evofem Plan To Regain Listing Compliance
Brief: Evofem Completes Enrollment In Evoguard Phase 3 Clinical Trial Of Evo100 For Prevention Of Chlamydia And Gonorrhea In Women
Evofem Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Evofem Biosciences Posts Q4 Loss Per Share Of $0.33
Evofem Biosciences Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Evofem Biosciences Staff Notified Co That Its Securities Were Subject To Delisting Unless It Timely Requested A Hearing Panel
Brief: Evofem Biosciences Inc - Seven Knots Agreed To Purchase Until March 1, 2024, Shares Of Up To $50 Million
Brief: Evofem Biosciences Inc - On Feb 15, Co Entered Into Common Stock Purchase Agreement With Seven Knots, Llc
Brief: FDA Awards QIDP Designation For Prevention Of Chlamydia To Evofem Biosciences
Brief: Evofem Biosciences Announces Record Net Sales And Phexxi Prescriptions In Q4 2021
U.S. RESEARCH ROUNDUP-Amicus Therapeutics, Five Below, ResMed
Brief: Phexxi Access To Expand Under New Government Guidance Stating Insurers Must Cover FDA-Approved Contraceptives With No Out-Of-Pocket Costs To Women
U.S. STOCKS ON THE MOVE-Adobe, Accenture, Under Armour, Novavax
U.S. STOCKS ON THE MOVE-Tesla, Delta Air Lines, Accenture, Calliditas Therapeutics
Evofem rises on drug development collaboration with Canada's Orion
Brief: Evofem Biosciences and Orion Biotechnology Launch Collaboration to Develop MPT Product Candidate to Include HIV Prevention
Brief: Evofem Biosciences Files Amendment To Certificate Of Incorporation
Evofem jumps on strong Q4 growth forecast for vaginal gel
Brief: Evofem Biosciences Expects Record High Phexxi Prescriptions And Strong Net Revenue Growth In Fourth Quarter 2021